U.S. markets open in 4 hours 41 minutes

Qiagen N.V. (QGEN)

NYSE - NYSE Delayed Price. Currency in USD
49.31-0.23 (-0.46%)
At close: 04:00PM EST
49.31 -0.02 (-0.04%)
After hours: 04:11PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close49.54
Bid49.28 x 1200
Ask0.00 x 800
Day's Range48.90 - 49.44
52 Week Range40.38 - 51.30
Avg. Volume725,218
Market Cap11.228B
Beta (5Y Monthly)0.38
PE Ratio (TTM)24.41
EPS (TTM)2.02
Earnings DateFeb 07, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-20% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for QGEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Qiagen N.V.
    Analyst Report: Qiagen N.V.Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (45% of 2021 sales), followed by EMEA (36%) and Asia-Pacific (19%).
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
  • Benzinga

    Genetic Technologies Shares Jump After Strategic Alliance With Qiagen

    Genetic Technologies Limited (NASDAQ: GENE) agreed to form a strategic alliance with Qiagen NV (NYSE: QGEN) to establish and develop a 'Centre of Excellence facility in Australia. Qiagen will support the improvement of GTG capabilities through software, hardware, consumable and technical solutions. Genetic Technologies CEO Simon Morriss said it was an exciting opportunity for the company. "We are extremely excited to be forming this alliance with the regional subsidiary of such a prestigious glo

  • Zacks

    Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?

    Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Zacks

    Qiagen (QGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.